HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Energizer Q1

This article was originally published in The Rose Sheet

Executive Summary

Blade and razor sales grew 12% to $228.2 mil. in the fiscal first quarter (ended Dec. 31), driven by performances of Schick Quattro and Intuition, company reports Jan. 25. Profit for the division jumped 20% to $41.4 mil. Consolidated sales increased 8%, or 5% on a constant currency basis, to $875.9 mil., and net earnings were $121.7 mil., or $1.62 per diluted share, up 6% versus the prior year. Release of firm's first quarter results coincides with start of Ward Klein's tenure as CEO. Energizer announced Klein, who previously served as chief operating officer, would succeed CEO Pat Mulcahy last year (1"The Rose Sheet" Nov. 8, 2004, p. 7)...

You may also be interested in...

Energizer Exec Klein Likely To Offer Smooth Management Transition

Energizer chief operating officer and longtime executive Ward Klein will take over leadership of the firm as CEO, succeeding Pat Mulcahy, who will retire following the firm's annual shareholder meeting on Jan. 25, the firm announced Nov. 2

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts